On April 11, 2022, the Board of Directors of Sera Prognostics, Inc. appointed Jane F. Barlow, M.D., MPH, MBA, effective April 11, 2022, as a director to the Board to serve as a Class I Director with a term expiring at the Company's 2022 annual meeting of stockholders. Dr. Barlow has served as Chief Executive Officer of Jane Barlow & Associates, LLC, a consulting firm focused on value-based health care services, since January 2017, and Executive Vice President and Chief Clinical Officer at Real Endpoints, a data, analytics, and advisory firm, since January 2017. She currently serves on the board of directors of ContraFect Corp., a publicly traded biotechnology company, and Viracta Therapeutics, Inc., a publicly traded precision oncology company.